Details of the Drug Reposition

General Information of This Drug (ID: DM4LKFO)

Drug Name
NELOTANSERIN   DM4LKFO
Synonyms
NELOTANSERIN; 839713-36-9; UNII-4ZA73QEW2P; 4ZA73QEW2P; CHEMBL598172; APD125; APD-125; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea; 1-[3-(4-BROMO-1-METHYL-1H-PYRAZOL-5-YL)-4-METHOXYPHENYL]-3-(2,4-DIFLUOROPHENYL)UREA; N-[3-(4-bromo-1-methyl-1H-pyrazol-5-yl)-4-methoxyphenyl]-N'-(2,4-difluorophenyl)-Urea; Nelotanserin [USAN:INN]; Nelotanserin (USAN/INN); SCHEMBL2345325; APD 125; DTXSID40232868; COSPVUFTLGQDQL-UHFFFAOYSA-N; BCP24992; ZINC38239930; BDBM50324541; AKOS027255058; DB12555
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Lewy body dementia DISAE66J 6D82 Phase 2 [1]
------------------------------------------------------------------------------------
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Sleep-wake disorder DISOBM0Q 7A00-7B2Z Discontinued in Phase 2 [2]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021795)